Navigation Links
Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
Date:4/10/2008

DALLAS, April 10 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that its collaborators at prestigious institutes in France and Italy will be presenting new preclinical data on its lead anticancer compound, ProLindac(TM), at the American Association for Cancer Research (AACR) Annual Meeting 2008 taking place April 12-16, 2008 at the San Diego Convention Center. The poster presentation entitled "Characterization of predictive markers and target genes of ProLindac, a novel DACH-platinum compound, compared to oxaliplatin and cisplatin in human cancer cell lines" will be presented on Monday April 14 from 1:00pm to 5:00pm in the "Novel Targets and Mechanisms 2" session held in Exhibit Hall B-F.

ProLindac is Access' novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin(TM) or oxaliplatin, which has sales in excess of $2 billion.

"We are grateful for the work and data our European collaborators are presenting at this prestigious meeting next week," stated Jeffrey B. Davis, Access' President & CEO. "As we continue to collect clinical and preclinical data on ProLindac, we are increasingly encouraged and excited about the potential of ProLindac to become a very important tool in the fight against cancer. In the ongoing recurrent ovarian trial, ProLindac continues to show significant DACH platinum anti-cancer activity, with significant reductions in CA-125 biomarkers and anti-tumor activity. We are seeing responses which suggest that ProLindac could be more active as a monotherapy in this patient population than was previously reported for carboplatin and oxaliplatin. Importantly, the side effect profile continues to be quite benign in comparison to other platinum therapies."

ProLindac is currently in a Phase 2 dose-escalating monotherapy trial in recurrent ovarian cancer. Access is currently in the process of planning additional ProLindac clinical trials that will include combination therapy trials in one or more solid tumor types.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Report on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Legislation Would Expedite Medicare Patient Access to Physical Therapy
2. SurgiQuest Announces First Procedure Using AirSeal(TM) Access System
3. Medicare Advantage Plans Have New, Better Way to Access CMS Data
4. Stryker to Provide Webcast and Telephone Access to Annual Shareholder Meeting
5. Increasing access to antiretroviral drugs would drastically cut AIDS deaths in South Africa
6. Open Biosystems Open Access RNAi Program Continues to Gain Momentum Worldwide
7. Toms of Maine Helps Increase Access to Dental Care
8. Medicare Bidding Program for Durable Medical Equipment May Harm Small Businesses and Decrease Patient Access to Care, Say 137 Members of Congress
9. Cardinal Health, GE Healthcare Broaden Relationship to Offer Greater Access to Myoview(TM) Imaging Agent
10. Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvanias Uninsured
11. Country Music Star Troy Gentry Partners With National Non-Profit Patient Advocate Foundation to Spread the Message About Challenges to Healthcare Access for Insured and Uninsured Americans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... ... replacement options at his office, Antoine Dental Center. Currently, patients can get single ... restrictions may apply, but patients can learn more about these offers by contacting ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic variants implicated ... to eight genes that may explain why susceptibility to one of the disorders could ... study published today in the journal npj Schizophrenia. , “There is a wealth ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, ... priority because it’s not if you will be attacked, but when.” However, he and ... to digital health care. , Improvements in auditing and monitoring have taken security in ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal ... Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, ... his attempts to overcome them. , Schanssema, initially unsure of the career path he ...
(Date:2/24/2017)... Abilene, Texas (PRWEB) , ... February 24, 2017 , ... ... article that focuses on Bible Prophecy concerning this present generation. Yisrayl makes an ... of this current generation. He explains that the Bible details the current times ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017 Visiomed, the French leader in ... is changing the landscape of healthcare with their ... pro-active, custom-made solutions. Recognizing the rising demand of ... healthcare without walls, Visiomed has launched BewellConnect, the ... healthcare professionals that is empowering the lives of ...
(Date:2/23/2017)... LG Innotek hat heute die weltweit erste ... das 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C ... und 280 nm und eignet sich damit für Sterilisationsaufgaben. Es ... zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung im ... ...
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
Breaking Medicine Technology: